Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma

被引:40
|
作者
Siegel, Matthew B. [1 ]
Liu, Selina Qiuying [1 ]
Davare, Monika A. [1 ,2 ]
Spurgeon, Stephen E. [1 ]
Loriaux, Marc M. [1 ]
Druker, Brian J. [1 ,3 ]
Scott, Emma C. [1 ]
Tyner, Jeffrey W. [1 ]
机构
[1] Knight Canc Inst, Portland, OR 97239 USA
[2] Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97201 USA
[3] Howard Hughes Med Inst, Portland, OR USA
关键词
BET; bromodomain; bortezomib; resistance; myeloma; MANTLE CELL LYMPHOMA; MULTIPLE-MYELOMA; C-MYC; PROTEASOME INHIBITION; THERAPEUTIC TARGET; BET BROMODOMAINS; ER STRESS; IN-VITRO; APOPTOSIS; NVP-BEZ235;
D O I
10.18632/oncotarget.4214
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Despite significant therapeutic progress in multiple myeloma, drug resistance is uniformly inevitable and new treatments are needed. Our aim was to identify novel, efficacious small-molecule combinations for use in drug resistant multiple myeloma. Experimental Design: A panel of 116 small molecule inhibitors was used to screen resistant myeloma cell lines for potential therapeutic targets. Agents found to have enhanced activity in the bortezomib or melphalan resistant myeloma cell lines were investigated further in combination. Synergistic combinations of interest were evaluated in primary patient cells. Results: The overall single-agent drug sensitivity profiles were dramatically different between melphalan and bortezomib resistant cells, however, the bromodomain inhibitor, CPI203, was observed to have enhanced activity in both the bortezomib and melphalan resistant lines compared to their wild-type counterparts. The combination of bortezomib and CPI203 was found to be synergistic in both the bortezomib and melphalan resistant cell lines as well as in a primary multiple myeloma sample from a patient refractory to recent proteasome inhibitor treatment. The CPI203-bortezomib combination led to enhanced apoptosis and anti-proliferative effects. Finally, in contrast to prior reports of synergy between bortezomib and other epigenetic modifying agents, which implicated MYC downregulation or NOXA induction, our analyses suggest that CPI203-bortezomib synergy is independent of these events. Conclusion: Our preclinical data supports a role for the clinical investigation of the bromodomain inhibitor CPI203 combined with bortezomib or alkylating agents in resistant multiple myeloma.
引用
收藏
页码:18921 / 18932
页数:12
相关论文
共 50 条
  • [31] IDO Inhibitor and Gallic Acid Cross-Linked Small Molecule Drug Synergistic Treatment of Melanoma
    Liu, Hongmei
    Gao, Huan
    Chen, Cheng
    Jia, Wenyu
    Xu, Delong
    Jiang, Guan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [32] A Small Molecule Screen in Stem-Cell-Derived Motor Neurons Identifies a Kinase Inhibitor as a Candidate Therapeutic for ALS
    Yang, Yin M.
    Gupta, Shailesh K.
    Kim, Kevin J.
    Powers, Berit E.
    Cerqueira, Antonio
    Wainger, Brian J.
    Ngo, Hien D.
    Rosowski, Kathryn A.
    Schein, Pamela A.
    Ackeifi, Courtney A.
    Arvanites, Anthony C.
    Davidow, Lance S.
    Woolf, Clifford J.
    Rubin, Lee L.
    CELL STEM CELL, 2013, 12 (06) : 713 - 726
  • [33] The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma
    Esteve-Arenys, A.
    Valero, J. G.
    Chamorro-Jorganes, A.
    Gonzalez, D.
    Rodriguez, V.
    Dlouhy, I.
    Salaverria, I.
    Campo, E.
    Colomer, D.
    Martinez, A.
    Rymkiewicz, G.
    Perez-Galan, P.
    Lopez-Guillermo, A.
    Roue, G.
    ONCOGENE, 2018, 37 (14) : 1830 - 1844
  • [34] The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells
    Pei, XY
    Dai, Y
    Grant, S
    LEUKEMIA, 2003, 17 (10) : 2036 - 2045
  • [35] The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells
    X-Y Pei
    Y Dai
    S Grant
    Leukemia, 2003, 17 : 2036 - 2045
  • [36] A drug combination screen identifies taxanes as synergistic agents with the oral IAP inhibitor Debio 1143 in non-small cell lung cancer cells.
    Langdon, Casey G.
    Wiedemann, Norbert
    Held, Mathew A.
    Platt, James T.
    Levy, Frederic
    Zanna, Claudio
    Vuagniaux, Gregoire
    Sorensen, Mel
    Wang, Shaomeng
    Bosenberg, Marcus W.
    Stern, David F.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [37] Anti-myeloma activity of the small-molecule Aurora kinase inhibitor VE465.
    Negri, Joseph M.
    McMillin, Douglas W.
    Mitsiades, Nicholas
    Hideshima, Teru
    Chauhan, Dharminder
    Tai, Yu-Tzu
    Leleu, Xavier
    Munshi, Nikhil C.
    Richardson, Paul G.
    Buser-Doepner, Carolyn A.
    Pollard, John
    Anderson, Kenneth C.
    Mitsiades, Constantine S.
    BLOOD, 2006, 108 (11) : 989A - 989A
  • [38] The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma
    A. Esteve-Arenys
    J. G. Valero
    A. Chamorro-Jorganes
    D. Gonzalez
    V. Rodriguez
    I. Dlouhy
    I. Salaverria
    E. Campo
    D. Colomer
    A. Martinez
    G. Rymkiewicz
    P. Pérez-Galán
    A. Lopez-Guillermo
    G. Roué
    Oncogene, 2018, 37 : 1830 - 1844
  • [39] CCS1477: A Novel Small Molecule Inhibitor of p300/CBP Bromodomain for the Treatment of Acute Myeloid Leukaemia and Multiple Myeloma
    Brooks, Nigel
    Raja, Meera
    Young, Barbara W.
    Spencer, Gary J.
    Somervaille, Tim C. P.
    Pegg, Neil A.
    BLOOD, 2019, 134
  • [40] A Small-Molecule Inhibitor Screen Rapidly Identifies Therapeutic Targets and Individualized Therapeutic Strategies In Patients with Acute and Chronic Leukemias
    Tyner, Jeffrey W.
    Spurgeon, Stephen
    Fletcher, Luke B.
    Yang, Wayne
    Kovacsovics, Tibor
    Druker, Brian J.
    Loriaux, Marc M.
    BLOOD, 2010, 116 (21) : 1136 - 1136